Conclusion: Not a LoopholeA Signal for the Future of Personalized Medicine The rise of compounding isnt an aberration
These reduced costs, combined with our unique lifestyle support system that drives 29% greater weight loss than the drugs alone, will continue to help Weight Watchers deliver the best GLP-1 results on the market. The expanded collaboration builds on Weight Watchers long-standing relationship with Novo Nordisk and reflects a shared commitment from both Weight Watchers and Novo Nordisk to improve access to FDA-approved weight health treatment
consistently high = not an everyday choice
On October 30, 2024, FDA removed semaglutide from its shortage list, so companies making and distributing compounded copies are now required to stop in their tracks as well
Recalls & Warnings June 26, 2024 FDA Warns Consumers Not to Use Infla-650 Due to Undeclared Drugs On June 20, 2024, the FDA warned consumers not to purchase or use Infla-650 after FDA laboratory analysis found them to contain acetaminophen, diclofenac, and phenylbutazone